No Data
No Data
Fuyuan Pharmaceutical (601089.SH): Agomelatine Tablets Obtained Pharmaceutical Registration Certificate.
On August 6th, Gelonhui reported that Fuyuan Pharmaceutical (601089.SH) has received the Drug Registration Certificate (Certificate No. 2024S01826) of Agomelatine Tablets (specification: 25mg) developed by French company Servier, a new type of melatonin-like drug. The drug was first approved for marketing in the European Union in 2009, and approved by the National Medical Products Administration in 2010. Agomelatine tablets are now available in China and are used to treat adult depression.
Fuyuan Pharmaceutical(601089.SH) has repurchased a total of 2.50% of its shares.
On August 1st, Gelunhui reported that Fuyuan Pharmaceutical (601089.SH) has disclosed that as of July 31, 2024, the company has repurchased 12,000,000 shares through centralized bidding trading, accounting for approximately 2.50% of the total share capital. The highest transaction price was 15.59 yuan/share and the lowest price was 13.59 yuan/share. The total amount paid was 176,169,816.92 yuan (excluding transaction fees).
Fuyuan Pharmaceutical (601089.SH): Huakang Taifeng promises not to reduce its shareholding in the company in any way within 12 months.
On July 29th, Gelunhui reported that Fuyuan Pharmaceutical (601089.SH) announced that, based on confidence in the company's future development prospects and recognition of its long-term investment value, in order to effectively protect the rights and interests of investors, Huakang Taifeng promised not to reduce its shareholding in the company in any way from July 30, 2024 to July 29, 2025, a period of 12 months. During the above-mentioned commitment period, Huakang Taifeng will also abide by the aforementioned non-reduction commitment for newly added shares due to capital reserve conversion, distribution of share dividends, allotment of shares, and issuance, among other reasons.
Fuyuan Pharmaceutical (601089.SH): The registration certificate for pharmaceutical Kansuimometasone ointment has been obtained.
On July 19th, Gelunhui reported that Fuyuan Medicine (601089.SH) announced that its wholly-owned subsidiary, Fuyuan Pharmaceutical Co., Ltd. (referred to as "Fuyuan Pharmaceutical") has received the Drug Registration Certificate (Certificate No.: 2024S01690) of Kansuang Mometasone Furoate Cream [0.1% (15g: 15mg), abbreviated as "the drug"], issued by the National Medical Products Administration. The drug is used for the treatment of eczema, neurodermatitis and skin itchiness.
Fuyuan Pharmaceutical (601089.SH): Fluorometholone acetate cream has obtained the pharmaceutical registration certificate.
On July 16th, Glonhui reported that Fuyuan Pharmaceutical (601089.SH), a wholly-owned subsidiary of Fuyuan Medicine, has received the Drug Registration Certificate for fluocinonide acetic acid cream [Specification: 0.05% (15g:7.5mg)]. This product is a topical glucocorticoid suitable for adults and children aged one year and above, used to relieve inflammation and itching symptoms of skin diseases that respond to glucocorticoids.
Fuyuan Pharmaceutical (601089.SH): the company did not repurchase shares in June.
On July 1st, Gelon Hui reported that in June 2024, Fuyuan Medical (601089.SH) did not repurchase any shares. As of June 30th, 2024, the company has already repurchased a total of 10,018,000 shares through centralized bidding trading, accounting for approximately 2.09% of the company's total share capital. The highest transaction price was 15.59 yuan/share, the lowest price was 14.37 yuan/share, and the total amount paid was 148,612,482.92 yuan (excluding transaction fees).
No Data